Overview

A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma

Status:
Terminated
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine the Maximum Tolerated Dose (MTD) and efficacy of the combined treatment of Temsirolimus and Sunitinib for the treatment of Advanced Kidney Cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Everolimus
Sirolimus
Sunitinib